A 2020 systematic review found that short-term use may have benefits, but long-term use can elevate fasting TMAO.28 From a prevention standpoint in relation to a number of chronic diseases, we are already encouraging people to decrease intake of red meat, Lampe says
MK-677 also significantly increases appetite and can raise fasting glucose
DSIP is known for its role in regulating sleep-wake cycles, stress responses, and endocrine function
08/12/2021 | Hng dn cch ng k xt nghim theo di vim gan B ti nh 1
Related Reading Ro Wegovy Mochi Wegovy Noom Wegovy Hims Wegovy Pricing and availability current as of June 2026

Who Experiences More Side Effects: Higher Risk of Side Effects: Women (higher rates than men) Starting at higher doses Rapid dose escalation History of GI issues (GERD, IBS) Slower metabolism Older age Lower Risk of Side Effects: Men (lower rates than women) Gradual dose escalation Prior GLP-1 exposure Following dietary recommendations Managing Side Effects Successfully: Diet Modifications: Foods to Emphasize: Lean proteins (chicken, fish, eggs) Non-starchy vegetables Clear broths and soups Crackers, toast (for nausea) Ginger (natural anti-nausea) Peppermint tea Foods to Avoid: Fatty, greasy foods (worsen nausea) Spicy foods (irritate GI tract) Large portions (harder to digest) Carbonated drinks (increase bloating) Alcohol (worsens nausea, dehydration) High-sugar foods (blood sugar swings) Eating Strategies: Small, frequent meals (5-6 times daily) Eat slowly, chew thoroughly Stop when satisfied (dont push to full) Stay upright after eating (prevents reflux) Dont drink large amounts with meals When to Contact Your Provider: Urgent (Call Immediately): Severe abdominal pain Persistent vomiting (cant keep fluids down) Signs of dehydration (dark urine, dizziness, confusion) Severe allergic reaction Vision changes Symptoms of pancreatitis Non-Urgent (Schedule Appointment): Side effects not improving after 4 weeks Want to discuss slowing dose escalation Questions about managing side effects Considering anti-nausea medication Weight loss plateau concerns Discontinuation Rates: Due to Side Effects: Semaglutide: 6.9% discontinue Tirzepatide: 6.2% discontinue Over 93% of patients tolerate well enough to continue Long-Term Safety: Semaglutide: On market since 2017 (8 years) Extensive real-world safety data SELECT trial: Actually reduced cardiovascular events (20% reduction) No new safety concerns with longer use Tirzepatide: On market since 2022 (3 years) Growing real-world safety data Clinical trials show excellent safety profile Cardiovascular outcomes trial ongoing Both medications appear safe for long-term use based on available evidence
